jcm-logo

Journal Browser

Journal Browser

Sarcopenia: Prevention and Treatment Options

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Geriatric Medicine".

Deadline for manuscript submissions: 20 July 2026 | Viewed by 582

Editor


E-Mail
Guest Editor
Neuroscience Research Australia, Sydney, NSW 2031, Australia
Interests: sarcopenia; frailty; fall prevention; exercise; ageing

Special Issue Information

Dear Colleagues,

Sarcopenia refers to the age-related loss of muscle strength, mass and physical performance and is associated with the increased risk of falls and fractures, functional impairment, frailty and mortality. The recognition of sarcopenia as a disease by the International Classification of Diseases in 2016 alongside recent efforts through the “Global Leadership Initiative in Sarcopenia” to establish a global conceptual definition of sarcopenia has facilitated research on interventions to prevent and treat sarcopenia. These interventions typically focus on a combination of nutrition and exercise, with growing interest in pharmacological strategies. With the ageing global population, such interventions aimed at preventing and treating sarcopenia are essential to maximise quality of life and reduce the burden on healthcare systems.

This Special Issue aims to highlight the latest evidence available for the prevention and treatment of sarcopenia which can translate to and inform clinical practice. We invite the submission of manuscripts (articles or reviews) from all fields that will contribute to furthering knowledge in the prevention and treatment of sarcopenia.

Dr. Steven Phu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sarcopenia
  • skeletal muscle
  • ageing
  • falls
  • frailty
  • exercise
  • rehabilitation
  • nutrition

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 665 KB  
Article
Comparison of Denosumab and Bisphosphonates for Sarcopenia in Postmenopausal Osteoporosis
by Seda Karaaslan Yetemen, Erhan Hocaoglu and Erdinc Erturk
J. Clin. Med. 2026, 15(13), 5010; https://doi.org/10.3390/jcm15135010 - 27 Jun 2026
Viewed by 222
Abstract
Background: The objective of this study was to compare the effects of bisphosphonates and denosumab on sarcopenia-related parameters, contributing to a better understanding of osteosarcopenia management. Methods: This cross-sectional, comparative study assessed physical performance, muscle strength, muscle mass, and sarcopenia category in postmenopausal [...] Read more.
Background: The objective of this study was to compare the effects of bisphosphonates and denosumab on sarcopenia-related parameters, contributing to a better understanding of osteosarcopenia management. Methods: This cross-sectional, comparative study assessed physical performance, muscle strength, muscle mass, and sarcopenia category in postmenopausal women aged 65 to 80 years with osteoporosis who were receiving either bisphosphonates or denosumab. Additional groups consisted of untreated osteoporotic patients and controls without osteoporosis (n = 50 per group). Muscle mass was assessed using bioelectrical impedance analysis, and the classification of sarcopenia was assessed according to the EWGSOP2 criteria. Results: Among the osteoporotic groups, the 4 m walking speed, 5-chair stand test, and timed up-and-go performance did not differ significantly, although denosumab-treated patients had numerically shorter completion times. Nondominant handgrip strength was the only grip parameter showing a significant between-group difference (p = 0.026), mainly due to higher values in denosumab-treated patients than in untreated osteoporotic patients; dominant and maximum handgrip strength were comparable. Skeletal muscle mass was higher in the denosumab group than in both the bisphosphonate-treated and untreated osteoporosis groups (p = 0.045), whereas ALM, ASM, and the ASMI did not differ significantly. No statistically significant between-group differences were observed in SARC-F scores or sarcopenia classifications. Controls had significantly higher odds of sarcopenia absence compared with untreated osteoporotic patients, and treatment duration was not correlated with sarcopenia-related parameters. Conclusions: These findings suggest a favorable but limited association between denosumab treatment and selected muscle-related parameters. Prospective longitudinal studies are needed to determine whether anti-osteoporotic therapies influence osteosarcopenia. Full article
(This article belongs to the Special Issue Sarcopenia: Prevention and Treatment Options)
Show Figures

Figure 1

Back to TopTop